| Parameter |
Oct2 + / |
BCL6 + / |
IRF8 + / |
OCAB + / |
PU.1 + / |
| Total (%) |
Total (%) |
Total (%) |
Total (%) |
Total (%) |
| Sex |
| Male |
34/39 (87.2) |
22/39 (56.4) |
22/39 (56.4) |
18/39 (46.1) |
11/39 (28.2) |
| Female |
30/34 (88.2) |
18/34 (52.9) |
22/34 (64.7) |
21/34 (61.7) |
7/34 (20.6) |
| Age |
| ≤ 60 |
31/36 (86.1) |
20/36 (55.5) |
21/36 (58.3) |
21/36 (58.3) |
8/36 (22.2) |
| > 60 |
33/37 (89.2) |
20/37 (54.0) |
23/37 (62.2) |
18/37 (48.6) |
10/37 (27.0) |
| DLBCL Stage |
| I |
14/17 (82.4) |
11/17 (64.7) |
14/17 (82.4) |
14/17 (82.4) |
14/17 (82.4) |
| II |
23/26 (88.5) |
14/26 (53.8) |
23/26 (88.5) |
23/26 (88.5) |
23/26 (88.5) |
| III |
13/15 (86.7) |
6/15 (40.0) |
13/15 (86.7) |
13/15 (86.7) |
13/15 (86.7) |
| IV |
13/14 (92.9) |
8/14 (57.1) |
13/14 (92.9) |
13/14 (92.9) |
13/14 (92.9) |
| LDH serumlevels |
| Normal |
13/15 (86.7) |
8/15 (53.3) |
10/15 (66.7) |
6/15 (40.0) |
2/15 (13.3) |
| Up |
20/21 (95.2) |
10/11 (90.9) |
14/21 (66.7) |
12/21 (57.1) |
4/21 (19.0) |
| Extranodaldisease |
| Absent |
22/27 (81.5) |
14/27 (51.8) |
15/27 (55.5) |
12/27 (44.4) |
2/27 (7.4) |
| Present |
27/29 (93.1) |
15/29 (51.7) |
18/29 (62.0) |
20/29 (69.0) |
9/29 (31.0) |
| B symptoms |
| Absent |
42/49 (85.7) |
31/49 (63.3) |
27/49 (55.1) |
27/49 (55.1) |
15/49 (30.6) |
| Present |
21/23 (91.3) |
8/23 (34.8) |
16/23 (69.6) |
11/23 (47.8) |
3/23 (13.0) |
|
| Pearson Chi Square Test: NS |
| Note: No association was found between Oct2, BCL6, IRF8, OCAB or PU.1 expression and the clinical and pathological parameters currently considered as relevant in DLBCL patients. The table shows the lack of correlation with sex, age, DLBCL stage, serum LDH level, extranodal disease and B symptoms, as examples. The entire set of data (clinical, pathological, phenotype markers and treatments) was collected from patient charts and analyzed in the same way applying the Chi Square Test. Other parameters included were DLBCL molecular phenotype (GCB and non-GCB), topography of lymph nodes involved, treatments received and patient response to therapy. |
| Table 2: No association was found between Oct2, BCL6, IRF8, OCAB or PU.1 expression and the clinical and pathological parameters currently considered as relevant in DLBCL patients. The table shows the lack of correlation with sex, age, DLBCL stage, serum LDH level, extranodal disease and B symptoms, as examples. The entire set of data |
